【译】在转移性结直肠癌影响总生存期KRAS测试吗?
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival?
目的:探讨西妥昔单抗联合化疗治疗转移性结直肠癌的疗效和不良反应。
Objective: to determine the therapeutic effect and toxicity of cetuximab and chemotherapy agents in metastatic colorectal cancer.
例如,委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。
For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.
方法:我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
方法:我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
应用推荐